AAPL339.75+0.77 (+0.23%) ▲|ABBV265.21+0.73 (+0.28%) ▲|ABT103.69+0.71 (+0.69%) ▲|ACN183.72-2.39 (-1.28%) ▼|ADBE238.25-11.27 (-4.52%) ▼|AMAT472.46+8.22 (+1.77%) ▲|AMD623.77+8.25 (+1.34%) ▲|AMGN410.24+17.08 (+4.34%) ▲|AMT175.25+0.65 (+0.37%) ▲|AMZN254.98-3.47 (-1.34%) ▼|AVGO364.54+1.88 (+0.52%) ▲|AXP305.07-8.52 (-2.72%) ▼|BA197.72-3.43 (-1.71%) ▼|BAC56.20-1.76 (-3.04%) ▼|BKNG164.22-4.30 (-2.55%) ▼|BLK1,066.66-23.61 (-2.17%) ▼|BMY62.25-0.37 (-0.59%) ▼|BNY150.17-3.72 (-2.42%) ▼|BRK-B503.49+1.48 (+0.29%) ▲|C132.47-2.58 (-1.91%) ▼|CAT808.01-8.49 (-1.04%) ▼|CL87.05+0.79 (+0.92%) ▲|CMCSA22.42-0.51 (-2.22%) ▼|COF200.55-4.37 (-2.13%) ▼|COP125.27-2.26 (-1.77%) ▼|COST899.41+0.93 (+0.10%) ▲|CRM233.28-3.14 (-1.33%) ▼|CSCO106.44-5.02 (-4.50%) ▼|CVS87.10-0.50 (-0.57%) ▼|CVX202.41-1.26 (-0.62%) ▼|DE703.12+18.39 (+2.69%) ▲|DHR221.09+5.25 (+2.43%) ▲|DIS103.82-0.41 (-0.39%) ▼|DUK116.31-0.43 (-0.37%) ▼|EMR154.19+2.47 (+1.63%) ▲|FDX295.94+0.15 (+0.05%) ▲|GD343.39-10.51 (-2.97%) ▼|GE319.22+0.21 (+0.07%) ▲|GEV950.28+4.06 (+0.43%) ▲|GILD152.67+2.11 (+1.40%) ▲|GM83.45-0.50 (-0.60%) ▼|GOOG347.41-3.46 (-0.99%) ▼|GOOGL351.16-3.81 (-1.07%) ▼|GS949.49-9.90 (-1.03%) ▼|HD305.35+8.15 (+2.74%) ▲|HON211.85+5.37 (+2.60%) ▲|IBM231.38-0.55 (-0.24%) ▼|INTC123.86+2.08 (+1.71%) ▲|INTU292.35-11.77 (-3.87%) ▼|ISRG402.09+0.44 (+0.11%) ▲|JNJ269.19-0.28 (-0.10%) ▼|JPM340.00-12.04 (-3.42%) ▼|KO88.61+1.49 (+1.71%) ▲|LIN464.91+7.41 (+1.62%) ▲|LLY1,170.14+5.25 (+0.45%) ▲|LMT522.34-13.06 (-2.44%) ▼|LOW196.08+5.10 (+2.67%) ▲|LRCX310.96+8.68 (+2.87%) ▲|MA555.89-11.76 (-2.07%) ▼|MCD250.35+2.47 (+1.00%) ▲|MDLZ61.08+0.91 (+1.51%) ▲|MDT90.77-0.98 (-1.07%) ▼|META736.60-4.65 (-0.63%) ▼|MMM169.30+4.33 (+2.62%) ▲|MO68.64+0.11 (+0.16%) ▲|MRK150.91+1.41 (+0.94%) ▲|MS200.18-5.94 (-2.88%) ▼|MSFT498.00-3.61 (-0.72%) ▼|MU1,096.16+52.20 (+5.00%) ▲|NEE79.26-0.37 (-0.46%) ▼|NFLX72.16-1.20 (-1.64%) ▼|NKE36.10+0.00 (+0.00%) ▲|NOW137.00-0.68 (-0.49%) ▼|NVDA228.87+1.49 (+0.66%) ▲|ORCL149.20+0.64 (+0.43%) ▲|PEP131.19+1.60 (+1.23%) ▲|PFE27.93+0.19 (+0.68%) ▲|PG148.22+2.14 (+1.47%) ▲|PLTR184.99+1.92 (+1.05%) ▲|PM190.23+2.75 (+1.47%) ▲|QCOM198.27+4.04 (+2.08%) ▲|RTX190.99-3.35 (-1.72%) ▼|SBUX95.11+0.21 (+0.22%) ▲|SCHW100.35-6.53 (-6.11%) ▼|SO85.15-0.31 (-0.36%) ▼|SPG205.95+0.97 (+0.47%) ▲|T25.10-0.35 (-1.38%) ▼|TMO658.52-0.24 (-0.04%) ▼|TMUS162.41-2.86 (-1.73%) ▼|TSLA378.90+3.69 (+0.98%) ▲|TXN271.41+0.54 (+0.20%) ▲|UBER69.89-0.95 (-1.34%) ▼|UNH372.95-4.61 (-1.22%) ▼|UNP274.41+4.78 (+1.77%) ▲|UPS95.87+1.12 (+1.18%) ▲|USB59.44-1.00 (-1.65%) ▼|V362.04-7.91 (-2.14%) ▼|VZ46.45-1.23 (-2.58%) ▼|WFC83.15-3.39 (-3.92%) ▼|WMT110.12+2.68 (+2.49%) ▲|XOM158.71+0.41 (+0.26%) ▲|AAPL339.75+0.77 (+0.23%) ▲|ABBV265.21+0.73 (+0.28%) ▲|ABT103.69+0.71 (+0.69%) ▲|ACN183.72-2.39 (-1.28%) ▼|ADBE238.25-11.27 (-4.52%) ▼|AMAT472.46+8.22 (+1.77%) ▲|AMD623.77+8.25 (+1.34%) ▲|AMGN410.24+17.08 (+4.34%) ▲|AMT175.25+0.65 (+0.37%) ▲|AMZN254.98-3.47 (-1.34%) ▼|AVGO364.54+1.88 (+0.52%) ▲|AXP305.07-8.52 (-2.72%) ▼|BA197.72-3.43 (-1.71%) ▼|BAC56.20-1.76 (-3.04%) ▼|BKNG164.22-4.30 (-2.55%) ▼|BLK1,066.66-23.61 (-2.17%) ▼|BMY62.25-0.37 (-0.59%) ▼|BNY150.17-3.72 (-2.42%) ▼|BRK-B503.49+1.48 (+0.29%) ▲|C132.47-2.58 (-1.91%) ▼|CAT808.01-8.49 (-1.04%) ▼|CL87.05+0.79 (+0.92%) ▲|CMCSA22.42-0.51 (-2.22%) ▼|COF200.55-4.37 (-2.13%) ▼|COP125.27-2.26 (-1.77%) ▼|COST899.41+0.93 (+0.10%) ▲|CRM233.28-3.14 (-1.33%) ▼|CSCO106.44-5.02 (-4.50%) ▼|CVS87.10-0.50 (-0.57%) ▼|CVX202.41-1.26 (-0.62%) ▼|DE703.12+18.39 (+2.69%) ▲|DHR221.09+5.25 (+2.43%) ▲|DIS103.82-0.41 (-0.39%) ▼|DUK116.31-0.43 (-0.37%) ▼|EMR154.19+2.47 (+1.63%) ▲|FDX295.94+0.15 (+0.05%) ▲|GD343.39-10.51 (-2.97%) ▼|GE319.22+0.21 (+0.07%) ▲|GEV950.28+4.06 (+0.43%) ▲|GILD152.67+2.11 (+1.40%) ▲|GM83.45-0.50 (-0.60%) ▼|GOOG347.41-3.46 (-0.99%) ▼|GOOGL351.16-3.81 (-1.07%) ▼|GS949.49-9.90 (-1.03%) ▼|HD305.35+8.15 (+2.74%) ▲|HON211.85+5.37 (+2.60%) ▲|IBM231.38-0.55 (-0.24%) ▼|INTC123.86+2.08 (+1.71%) ▲|INTU292.35-11.77 (-3.87%) ▼|ISRG402.09+0.44 (+0.11%) ▲|JNJ269.19-0.28 (-0.10%) ▼|JPM340.00-12.04 (-3.42%) ▼|KO88.61+1.49 (+1.71%) ▲|LIN464.91+7.41 (+1.62%) ▲|LLY1,170.14+5.25 (+0.45%) ▲|LMT522.34-13.06 (-2.44%) ▼|LOW196.08+5.10 (+2.67%) ▲|LRCX310.96+8.68 (+2.87%) ▲|MA555.89-11.76 (-2.07%) ▼|MCD250.35+2.47 (+1.00%) ▲|MDLZ61.08+0.91 (+1.51%) ▲|MDT90.77-0.98 (-1.07%) ▼|META736.60-4.65 (-0.63%) ▼|MMM169.30+4.33 (+2.62%) ▲|MO68.64+0.11 (+0.16%) ▲|MRK150.91+1.41 (+0.94%) ▲|MS200.18-5.94 (-2.88%) ▼|MSFT498.00-3.61 (-0.72%) ▼|MU1,096.16+52.20 (+5.00%) ▲|NEE79.26-0.37 (-0.46%) ▼|NFLX72.16-1.20 (-1.64%) ▼|NKE36.10+0.00 (+0.00%) ▲|NOW137.00-0.68 (-0.49%) ▼|NVDA228.87+1.49 (+0.66%) ▲|ORCL149.20+0.64 (+0.43%) ▲|PEP131.19+1.60 (+1.23%) ▲|PFE27.93+0.19 (+0.68%) ▲|PG148.22+2.14 (+1.47%) ▲|PLTR184.99+1.92 (+1.05%) ▲|PM190.23+2.75 (+1.47%) ▲|QCOM198.27+4.04 (+2.08%) ▲|RTX190.99-3.35 (-1.72%) ▼|SBUX95.11+0.21 (+0.22%) ▲|SCHW100.35-6.53 (-6.11%) ▼|SO85.15-0.31 (-0.36%) ▼|SPG205.95+0.97 (+0.47%) ▲|T25.10-0.35 (-1.38%) ▼|TMO658.52-0.24 (-0.04%) ▼|TMUS162.41-2.86 (-1.73%) ▼|TSLA378.90+3.69 (+0.98%) ▲|TXN271.41+0.54 (+0.20%) ▲|UBER69.89-0.95 (-1.34%) ▼|UNH372.95-4.61 (-1.22%) ▼|UNP274.41+4.78 (+1.77%) ▲|UPS95.87+1.12 (+1.18%) ▲|USB59.44-1.00 (-1.65%) ▼|V362.04-7.91 (-2.14%) ▼|VZ46.45-1.23 (-2.58%) ▼|WFC83.15-3.39 (-3.92%) ▼|WMT110.12+2.68 (+2.49%) ▲|XOM158.71+0.41 (+0.26%) ▲|
13.9 C
New York
Wednesday, September 23, 2026

Tag: year

newssourceFORcompanyinformationcontent1releasesmarket

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

Unlock Your Wealth: Smart AI and Crypto Investments for Confident Women

Hey lovely money mavens! 🌟 Let's chat about two exciting opportunities in the investment world that could seriously boost your financial game. We're diving...

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

China, Central Asia make continuous efforts to deepen agricultural cooperation

BEIJING, June 15, 2025 /PRNewswire/ -- A report from People's Daily: ...

Eve Air Mobility Twenty-Year Market Outlook Highlights Growth of Urban Air Mobility Globally

Outlook highlights a $280 billion passenger revenue and 30,000 aircraft opportunities driven by urban population growth, traffic concerns, and a commitment to sustainability. PARIS,...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

Cheap AI Bots Eye Junior Coders’ Lunch

In 2007, Luke Arrigoni pulled in $63,000 as a junior software developer. Fast forward to today, and AI tools that supposedly churn out better...

Prix Fitzgerald 2025 Laureate Announced at Hôtel Belles Rives

Renowned American Author Richard Ford Receives 14th Annual Literary Award for Be Mine 
Renowned American Author Richard Ford Receives 14th Annual Literary Award for Be Mine

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.

A.I. Saves Ad Industry—Until It Doesn’t.

The Cannes Lions Festival of Creativity, a glorified playground for ad executives who enjoy sipping overpriced cocktails while convincing themselves they're the maestros of...

Ram Brand Launches ‘Never Stop Being American’ Marketing Campaign, New Brand Ethos ‘Nothing Stops Ram’

"Never Stop Being American" marketing campaign takes off across broadcast and Ram brand's social media channelsCampaign celebrates America, its people, pastimes and traditions, formally...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsYear

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers